×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ATOS – atossa therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ATOS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/11
10:37 am
atos
Atossa gains on Rare Pediatric Disease status for Duchenne asset [Seeking Alpha]
Medium
Report
Atossa gains on Rare Pediatric Disease status for Duchenne asset [Seeking Alpha]
12/11
08:17 am
atos
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy [Yahoo! Finance]
Medium
Report
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy [Yahoo! Finance]
12/11
08:00 am
atos
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy
Medium
Report
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy
12/9
08:00 am
atos
Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen
Low
Report
Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen
12/8
08:07 am
atos
Atossa Genetics (NASDAQ:ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $7.75 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Atossa Genetics (NASDAQ:ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $7.75 to $8.00. They now have a "buy" rating on the stock.
12/4
08:00 am
atos
Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
Low
Report
Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
12/2
08:00 am
atos
Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma
Medium
Report
Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma
11/17
09:22 am
atos
Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation [Yahoo! Finance]
Medium
Report
Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
12/12
05:01 pm
atos
Form PRE 14A ATOSSA THERAPEUTICS, For: Dec 12
Medium
Report
Form PRE 14A ATOSSA THERAPEUTICS, For: Dec 12
12/4
08:15 am
atos
Form 8-K ATOSSA THERAPEUTICS, For: Dec 04
Low
Report
Form 8-K ATOSSA THERAPEUTICS, For: Dec 04
11/12
08:46 am
atos
Form 10-Q ATOSSA THERAPEUTICS, For: Sep 30
Low
Report
Form 10-Q ATOSSA THERAPEUTICS, For: Sep 30
11/12
08:40 am
atos
Form 8-K ATOSSA THERAPEUTICS, For: Nov 12
Low
Report
Form 8-K ATOSSA THERAPEUTICS, For: Nov 12
10/21
04:10 pm
atos
Form 4 ATOSSA THERAPEUTICS, For: Oct 14 Filed by: Daniel Mark James
Medium
Report
Form 4 ATOSSA THERAPEUTICS, For: Oct 14 Filed by: Daniel Mark James
10/21
04:05 pm
atos
Form 3 ATOSSA THERAPEUTICS, For: Oct 14 Filed by: Daniel Mark James
Medium
Report
Form 3 ATOSSA THERAPEUTICS, For: Oct 14 Filed by: Daniel Mark James
10/14
07:50 am
atos
Form 8-K ATOSSA THERAPEUTICS, For: Oct 14
Neutral
Report
Form 8-K ATOSSA THERAPEUTICS, For: Oct 14
9/26
05:13 pm
atos
Form 8-K ATOSSA THERAPEUTICS, For: Sep 26
Medium
Report
Form 8-K ATOSSA THERAPEUTICS, For: Sep 26
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/27
Atossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density
22.9%
3/30 New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients 10.3%
4/17 COVID-19 “Cease Fire” for the United States on April 23, 2020 and successful ‘Opening Up America Again’ initiative predicted 9.0%
10/16 Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology 7.6%
3/13 Atossa to meet with FDA on Endoxifen development [Seeking Alpha] 7.1%
5/21 Form 4 ATOSSA GENETICS INC For: May 17 Filed by: Steinhart Richard I 5.9%
3/26 Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update 4.8%
5/30 Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019 4.0%
4/13 Form 4 ATOSSA THERAPEUTICS, For: Apr 09 Filed by: Guse Kyle 3.4%
12/18 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. 2.5%
3/30 New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients 10.3%
4/17 COVID-19 “Cease Fire” for the United States on April 23, 2020 and successful ‘Opening Up America Again’ initiative predicted 9.0%
10/16 Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology 7.6%
3/13 Atossa to meet with FDA on Endoxifen development [Seeking Alpha] 7.1%
5/21 Form 4 ATOSSA GENETICS INC For: May 17 Filed by: Steinhart Richard I 5.9%
3/26 Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update 4.8%
5/30 Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019 4.0%
4/13 Form 4 ATOSSA THERAPEUTICS, For: Apr 09 Filed by: Guse Kyle 3.4%
12/18 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. 2.5%
TOP News Decliners
4/16
Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program
-26.0%
7/11 Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated -24.8%
4/27 Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study -21.9%
4/20 Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study -17.0%
5/13 Form 8-K ATOSSA GENETICS INC For: May 13 -10.6%
12/19 Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women -8.4%
4/2 Atossa Therapeutics Announces Clinical Progress -7.8%
6/27 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -4.9%
11/13 Form 10-Q ATOSSA GENETICS INC For: Sep 30 -4.7%
8/13 Q2/2019 6/30/2019 EPS -0.800 ZacksConsensus N/A ActVsEst N/A - N/A -4.5%
7/11 Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated -24.8%
4/27 Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study -21.9%
4/20 Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study -17.0%
5/13 Form 8-K ATOSSA GENETICS INC For: May 13 -10.6%
12/19 Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women -8.4%
4/2 Atossa Therapeutics Announces Clinical Progress -7.8%
6/27 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -4.9%
11/13 Form 10-Q ATOSSA GENETICS INC For: Sep 30 -4.7%
8/13 Q2/2019 6/30/2019 EPS -0.800 ZacksConsensus N/A ActVsEst N/A - N/A -4.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: